Sunshine Biopharma, Inc. (OTCMKTS:SBFM) Heats Up Fast
By Boe Rimes on June 3, 2020 Micro Cap Insider, Small Caps, Street Watch
Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is making a big move up after the Company anounced it has filed a patent application for a new coronavirus COVID-19 Treatment. The stock was trading in double zero land before the news and has been rocketing up since.
According to Sunshine Biopharma its patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. The patent application has a priority date of May 22, 2020.
Sunshine Biopharma, Inc. (OTCMKTS:SBFM) bills itself as a pharmaceutical company operating in the pharmaceutical testing services sector, as well as, in the research, development and commercialization of drugs for the treatment of cancer. Sunshine Biopharma’s business plan includes the clinical development of Adva-27a, the Company’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada.
Sunshine Biopharma conducts its operations through three (3) wholly owned subsidiaries: Atlas Pharma Inc. (“Atlas”), a Canadian company dedicated to chemical analysis of pharmaceutical and other industrial samples. Atlas’ operations are authorized by a Drug Establishment License issued by Health Canada. Atlas is also registered with the FDA.
Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian company formed in 2014 for the purposes of offering generic prescription pharmaceuticals in Canada and elsewhere around the world. Sunshine Canada has signed licensing agreements for four (4) generic prescription drugs for the treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia).
NOX Pharmaceuticals, Inc. (“NOX”) is a Colorado corporation dedicated to the research, development and commercialization of proprietary drugs including Adva27a, the Company’s flagship proprietary drug for the treatment of cancer. Adva-27a, is a small molecule that has proven effective against different types of multidrug resistant cancer including breast cancer cells (MCF-7/MDR), small-cell lung cancer cells (H69AR), uterine carcinoma cells (MES-SA/Dx5) and pancreatic cancer cells (Panc-1).
Microcapdaily has been covering SBFM for many years; on April 4, 2016 we covered the stock commenting “Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is making an explosive move up on accelerating volume since reversing off $0.0121 lows last week. The stock does have a history of big moves running from well under $0.25 to highs over $1.25 in 2011.[color=red][/color]
On June 3 SBFM announced it has filed a patent application in the United States for a new treatment for Coronavirus infections, including COVID-19. Sunshine’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. The patent application has a priority date of May 22, 2020.
“The causative agent of the current COVID-19 global pandemic is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins in infected human cells by cleaving them from two overlapping viral ‘polyproteins,’ pp1a and pp1ab. One of these functional proteins is a cysteine protease referred to as the main protease (Mpro, also called 3CLpro and nsp5). Mpro cleaves the viral ‘polyproteins’ at a number of specific sites thereby generating a multi-subunit protein complex termed ‘viral replicase-transcriptase’. Because of its functional indispensability in viral replication, Mpro is an attractive drug target for the development of a treatment for COVID-19 and other Coronavirus infections,” said Dr. Slilaty.
Currently racing up the charts SBFM has minimal asset, manageable debt and growing sales reporting $335,357 in revenues for the 9 months ended September 30, 2018. SBFM is an exciting story developing in small caps; SBFM is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of cancer. SBFM is making a big move up after the Company anounced it has filed a patent application for a new coronavirus COVID-19 Treatment. The stock was trading in double zero land before the news and has been rocketing up since. We will be updating on SBFM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SBFM.
Market Data 
Markets 
AI
